Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech's stock (MBRX) has experienced significant volatility and a substantial decline over the past year, with a decrease of approximately 77.87% in the last six months. Key events include a February 2026 warrant exercise and dilution, which caused the stock to drop due to potential dilution of existing shareholders. The MIRACLE trial reached its 45-subject enrollment milestone, triggering preparations for an interim unblinding of data. Preclinical data presented at AACR 2026 showed Annamycin extended survival in metastatic pancreatic cancer models. An abstract highlighting Annamycin data was accepted for poster presentation at the 2026 ASCO Annual Meeting. Moleculin announced the issuance of a Hong Kong patent covering its method of reconstituting liposomal Annamycin. The company released CEO Corner segments highlighting Annamycin's non-cardiotoxic profile.

As a clinical-stage pharmaceutical company, Moleculin Biotech, Inc. does not currently have commercially available products with established market demand seasonality. Demand for its future products will be driven by clinical efficacy, regulatory approvals, and the prevalence of the diseases they aim to treat.

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on developing therapeutic candidates for the treatment of highly resistant tumors and viruses, operating within the Healthcare sector and Biotechnology industry. Its primary product candidates include Annamycin, designed to avoid multidrug resistance and cardiotoxicity, in clinical development for AML and soft tissue sarcoma lung metastases. The WP1066 Portfolio includes immune/transcription modulators designed to inhibit p-STAT3 for brain tumors, pancreatic, and other cancers. The WP1122 Portfolio aims to exploit glycolysis inhibitors to cut off the energy supply of tumors and is being developed for potential treatment of viruses.

Moleculin Biotech, Inc. is headquartered in Houston, Texas, United States. Its clinical trials, like the MIRACLE trial for Annamycin, have a global reach with approved sites in the US, Europe, and the Middle East, including Georgia. The company has secured intellectual property protection for Annamycin through patents in various countries across North America, Europe, and Asia.

Moleculin Biotech's brand reputation has been influenced by positive clinical and intellectual property developments, alongside a significant decline in its stock price. Positive events include advancements in the Annamycin program, clinical trial progress with the MIRACLE trial, positive preclinical data for Annamycin in metastatic pancreatic cancer models, and intellectual property expansion with new patents. However, the company's stock performance and the substantial dilution from warrant exercises could negatively impact investor confidence and broader market perception.

Moleculin Biotech, Inc. has a significant portion of its ownership skewed towards individual investors, with institutional ownership being comparatively small, around 15.52%. Major institutional shareholders include Vanguard Group Inc., Geode Capital Management, Llc, and BlackRock, Inc. The largest individual shareholder is Co-Founder and Founding Scientist Waldemar Priebe, who owns approximately 12.04% of the company. Insider ownership is around 3.52%.